Literature DB >> 17065920

Lymphomas involving the eye and the ocular adnexa.

Sarah E Coupland1, Bertil Damato.   

Abstract

PURPOSE OF REVIEW: To describe recent advances in the understanding of the pathogenesis of the most common malignant lymphomas that occur as primary and secondary tumors in ocular tissues. RECENT
FINDINGS: Advances have been made in the understanding of the genetic alterations in mucosa-associated lymphoid tissue lymphomas, including various chromosomal translocations, such as the most recently described t(3;14)(p14.1;q32) involving the FOXP1 gene. Further, the development of ocular adnexal mucosa-associated lymphoid tissue lymphomas has been associated with Chlamydia psittaci in some geographic areas. Subdivision of diffuse large B-cell lymphoma into clinically prognostic groups had been achieved on the basis of gene expression profiles using complementary DNA microarrays. Tumor-infiltrating cells, such as macrophages, have been demonstrated to be of prognostic significance in follicular lymphoma.
SUMMARY: Understanding of the ocular adnexal and intraocular lymphomas has advanced with progress in lymphoma classification systems, namely the World Health Organization lymphoma classification. This knowledge is being fine tuned with advances in technology, such as complementary DNA microarrays. The clinical significance of this scientific progress has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065920     DOI: 10.1097/ICU.0b013e328010948d

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  16 in total

1.  Intraocular lymphoma following a primary testicular lymphoma in remission for 10 years.

Authors:  K Aliferis; C C Chan; G Donati; E Baglivo
Journal:  Int Ophthalmol       Date:  2007-11-06       Impact factor: 2.031

Review 2.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

3.  Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges.

Authors:  Timothy S Saunders; Sarah Anis; Yelena Doych; Anna Moran; J Steve Hou; Xiaoli Chen; Myron Yanoff
Journal:  Digit J Ophthalmol       Date:  2010-07-29

4.  Anterior Chamber Non-Hodgkin Lymphoma of the Iris Masquerading as Uveitis-Glaucoma-Hyphema Syndrome.

Authors:  Angela C Gauthier; Alexander Nguyen; William R Munday; Mina L Xu; Miguel A Materin
Journal:  Ocul Oncol Pathol       Date:  2016-05-12

Review 5.  Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.

Authors:  Dimitrios Kalogeropoulos; Alexandra Papoudou-Bai; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Clin Exp Med       Date:  2017-09-22       Impact factor: 3.984

Review 6.  [Lymphoma of the ocular adnexa].

Authors:  V Kakkassery; N Stübiger; I A Adamietz; I Tischoff; A Baraniskin; I M Wunderlich
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

7.  [Diagnostics and treatment of choroidal lymphoma].

Authors:  D Doycheva; M Zierhut; D Süsskind; K U Bartz-Schmidt; C Deuter
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

8.  Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report.

Authors:  D M Rasić; Z Stanković; T Terzić; D Kovacević; Z Koturović; V Marković
Journal:  Med Oncol       Date:  2009-10-09       Impact factor: 3.064

Review 9.  A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma.

Authors:  Maurilio Ponzoni; Silvia Govi; Giada Licata; Silvia Mappa; Antonio Giordano Resti; Letterio S Politi; Lorenzo Spagnuolo; Eliana Di Cairano; Claudio Doglioni; Andrés J M Ferreri
Journal:  Oncologist       Date:  2013-06-28

10.  [Non-Hodgkin lymphoma of the lacrimal gland].

Authors:  J Yayan; A Mallouhi; P Moser; E Irschick
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.